TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07652073: A Phase II Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of DAT-2645 in Patients With BRCA1/2 Deleterious Mutations or HRD-Positive Advanced/Metastatic Ovarian Cancer

Sponsor: Danatlas Pharmaceuticals Co., Ltd · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,652,800

Rescue Site Savings

+$4,389,000

Unlock Full NCT07652073 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07652073 Rescue Dossier →